Meningioma is the most common primary intracranial tumor in adults. Though the majority of tumors are slow growing, many patients fail first-line treatments with surgery and/or radiation. Others are poor surgical candidates for definitive surgical resection due to their age, tumor location or associated medical comorbidities. Few targeted therapies and biologics for meningioma are studied, and they have limited efficacy.
This study aims to estimate the overall survival, progression free survival, and safety of octreotide acetate (Sandostatin LAR) as a potential treatment for recurrent and/or refractory meningiomas. The retrospective chart review included patients over 18 years of age and diagnosed with meningioma who were administered Sandostatin LAR from 01/01/2010 until 06/01/2017 at the University of California, Irvine (UCI). The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoint was assessing safety.
There were 43 patients included in the chart review. 14 patients experienced disease progression and 6 died. The overall survival times at 6 months, 1 year, and 3 years for all WHO grades was 94.8% (0.88-1.01), 88.1% (0.77-0.99), and 67.0% (0.36-0.98) respectively. Median time to progression for grade 1, 2, and 3 were 3.1, 2.38, and 0.21 years respectively. The most common AE was diarrhea which occurred in 19 out of 47 patients. Overall, Sandostatin LAR was well tolerated.
This is the largest reported cohort of meningioma patients treated with Sandostatin LAR and suggests that Sandostatin LAR can be a well-tolerated treatment and prolong overall survival and progression free survival.